PHARM: Drugs for IBS Flashcards
What is the first line treatment of a patient with IBS?
education, reassurance, dietary modification (exclusion of gas producing foods), and increased physical activity
When is drug treatment warranted with IBS?
for moderate to severe symptoms that are not relieved by lifestyle changes
What type of IBS is treated with: Linaclotide, Lubiprostone, PEG?
IBS-C
What type of IBS is treated with: Alostetron, Loperamide, Anti-spasmodics (Atropine, Dicyclomine, Glycopyrrolate)
IBS-D
What type of IBS has: Hard or lumpy stools with ≥25% of BMs and loose watery stools with ≥25% of BMs?
IBS-M
What type of IBS has: Presence of loose or watery stools with with ≥25% of BMs and hard or lumpy stools with <25% of BMs?
IBS-D
What type of IBS has: Presence of hard or lumpy stools with ≥25% of BMs and loose watery stools with <25% of BMs?
IBS-C
MOA: Osmotic agent; binds water and causes it to be retained within the stool AND stimulates stretch receptors to increase cholinergic activity in the ENS.
PEG
MOA: Absorb liquid in GI tract; thereby altering intestinal fluid and electrolyte transport and causing stool expansion, increased peristalsis and bowel motility
Polycarbophil
Methylcellulose
Psyllium
MOA: Activates guanylate cyclase-C receptor to increase intracellular cGMP→ sitmulates secretion of Cl- and CHO3- from CFTR ion channel into intestinal lumen and the increased GI fluid increases the GI transit (via stretch)
Linaclotide
MOA: PGE1 derivative that directly activates plasma Cl- channel (ClC-2) to increase GI fluid secretion and accelerate motility (via stretch)
Lubiprostone
What drug is STRONGLY recommended for IBS-C?
Linaclotide
What is a contraindication for all IBS-C drugs?
Contraindicated in known/suspected obstruction.
What IBS-C drug is contraindicated in children <6?
Linaclotide
TOXICITY: Infrequent flatulence, nausea, abdominal pain, bloating and cramping
PEG
TOXICITY: Rarely abdominal pain or cramps, diarrhea, increased flatulence, N/V
Polycarbophil
Methylcellulose
Psyllium
TOXICITY: Diarrhea (usually within 2 weeks of treatment start)
Linaclotide
TOXICITY: Dose related nausea, HA, and diarrhea
Lubiprostone
MOA: Selective antagonist at 5-HT3 receptors extensively distributed on enteric neurons in GI tract.
Alosetron
MOA: Competitive post-ganglionic muscarinic receptor antagonist. (modulate activity in the enteric nervous system)
Atropine
Dicyclomine
Glycopyrrolate